Entering text into the input field will update the search result below

Biogen lays off more than 100 in wake of Aduhelm disappointment - Endpoints

Mar. 03, 2022 1:27 PM ETBiogen Inc. (BIIB)By: Jonathan Block, SA News Editor3 Comments

Close-up Of Unemployed Businessperson Carrying Cardboard Box

RUNSTUDIO/DigitalVision via Getty Images

Biogen (BIIB +2.3%) has laid off more than 100 workers -- the vast majority in its Alzheimer's division -- as a result of the commercial failure of its Alzheimer's treatment Aduhelm (aducanumab), Endpoints

Recommended For You

Comments (3)

Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

charged profile picture
Sorry they didn’t dump the ceo, board and committee that pushed this forward. That would be great savings.
smikhail profile picture
Good riddance.
Vitamanrocks1 profile picture
Biogen is also going to have to bribe more FDA officers to put holds on competitors studies, or outright CRL's.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.